isoproterenol has been researched along with Panic Disorder in 11 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effects of beta-adrenergic stimulation on R and T amplitude variability in panic disorder patients by infusing the beta-adrenergic agonist isoproterenol in 6 panic disorder patients and 11 normal subjects." | 9.12 | Exaggerated beat-to-beat R amplitude variability in patients with panic disorder after intravenous isoproterenol. ( Bär, KJ; Chokka, P; Pohl, R; Tancer, M; Yeragani, VK, 2007) |
| " We examined the effects of sympathetic stimulation on QT interval variability in panic disorder patients by infusing the ss-adrenergic agonist isoproterenol in 6 panic disorder patients and 11 normal subjects." | 7.71 | QT interval variability in panic disorder patients after isoproterenol infusions. ( K Yeragani, V; Pohl, R, 2001) |
| "Paroxetine was administered to all of the panic patients for 12 weeks." | 5.35 | beta-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder. ( Kang, EH; Kim, KJ; Lee, IS; Yu, BH, 2008) |
| "We examined the effects of beta-adrenergic stimulation on R and T amplitude variability in panic disorder patients by infusing the beta-adrenergic agonist isoproterenol in 6 panic disorder patients and 11 normal subjects." | 5.12 | Exaggerated beat-to-beat R amplitude variability in patients with panic disorder after intravenous isoproterenol. ( Bär, KJ; Chokka, P; Pohl, R; Tancer, M; Yeragani, VK, 2007) |
| "This study was conducted on patients with panic disorder (PD) to examine the gender differences in the pathophysiology of PD by evaluating and comparing the value of CD(25)/wt, the chronotropic 25 dose of isoproterenol (CD(25)) divided by the body weight, which reflects the in vivo index of beta-adrenergic receptor sensitivity." | 5.11 | Differences in beta-adrenergic receptor sensitivity between women and men with panic disorder. ( Kim, YR; Min, SK; Yu, BH, 2004) |
| "Lymphocyte beta adrenoreceptor density and affinity, basal lymphocyte cAMP level, and isoproterenol-stimulated cAMP generation were measured in 27 untreated outpatients with panic disorder with agoraphobia and 24 healthy comparison subjects." | 5.07 | Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia. ( Carter, CS; Gietzen, DW; Maddock, RJ; Magliozzi, JR, 1993) |
| "Plasma catecholamines and hemodynamics were examined in response to intravenous glucagon, yohimbine, and trimethaphan in 11 patients with pseudopheochromocytoma and a comparison group of nine normotensive and five hypertensive volunteers." | 3.74 | Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. ( Bentho, O; Eisenhofer, G; Geraci, MF; Goldstein, DS; Holmes, C; Pacak, K; Pechnik, S; Saleem, A; Sharabi, Y, 2007) |
| " We examined the effects of sympathetic stimulation on QT interval variability in panic disorder patients by infusing the ss-adrenergic agonist isoproterenol in 6 panic disorder patients and 11 normal subjects." | 3.71 | QT interval variability in panic disorder patients after isoproterenol infusions. ( K Yeragani, V; Pohl, R, 2001) |
| "Paroxetine was administered to all of the panic patients for 12 weeks." | 1.35 | beta-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder. ( Kang, EH; Kim, KJ; Lee, IS; Yu, BH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khalsa, SS | 1 |
| Feinstein, JS | 1 |
| Li, W | 1 |
| Feusner, JD | 1 |
| Adolphs, R | 1 |
| Hurlemann, R | 1 |
| Kim, YR | 1 |
| Min, SK | 1 |
| Yu, BH | 2 |
| Khurana, RK | 1 |
| Yeragani, VK | 2 |
| Pohl, R | 3 |
| Bär, KJ | 1 |
| Chokka, P | 1 |
| Tancer, M | 1 |
| Sharabi, Y | 1 |
| Goldstein, DS | 1 |
| Bentho, O | 1 |
| Saleem, A | 1 |
| Pechnik, S | 1 |
| Geraci, MF | 1 |
| Holmes, C | 1 |
| Pacak, K | 1 |
| Eisenhofer, G | 1 |
| Lee, IS | 1 |
| Kim, KJ | 1 |
| Kang, EH | 1 |
| Srinivasan, K | 1 |
| Balon, R | 1 |
| Ramesh, C | 1 |
| Berchou, R | 1 |
| Maddock, RJ | 2 |
| Gietzen, DW | 2 |
| Goodman, TA | 1 |
| Carter, CS | 1 |
| Magliozzi, JR | 1 |
| K Yeragani, V | 1 |
| Le Mellédo, JM | 1 |
| Arthur, H | 1 |
| Dalton, J | 1 |
| Woo, C | 1 |
| Lipton, N | 1 |
| Bellavance, F | 1 |
| Koszycki, D | 1 |
| Boulenger, JP | 1 |
| Bradwejn, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS): a Pilot Study[NCT04345432] | 10 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for isoproterenol and Panic Disorder
| Article | Year |
|---|---|
Differences in beta-adrenergic receptor sensitivity between women and men with panic disorder.
Topics: Adrenergic beta-Agonists; Adult; Catecholamines; Dose-Response Relationship, Drug; Female; Heart Rat | 2004 |
Experimental induction of panic-like symptoms in patients with postural tachycardia syndrome.
Topics: Adult; Cardiotonic Agents; Diagnosis, Differential; Female; Humans; Hypotension, Orthostatic; Isopro | 2006 |
Exaggerated beat-to-beat R amplitude variability in patients with panic disorder after intravenous isoproterenol.
Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Electrocardiography; Female; Heart Conduction | 2007 |
Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Anti-Anxiety Agents; Antidepressive Agents; Benzodiazepines; Cyclic AMP; Double- | 1993 |
The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiovascular Physiol | 2001 |
6 other studies available for isoproterenol and Panic Disorder
| Article | Year |
|---|---|
Panic Anxiety in Humans with Bilateral Amygdala Lesions: Pharmacological Induction via Cardiorespiratory Interoceptive Pathways.
Topics: Adrenergic beta-Agonists; Adult; Afferent Pathways; Amygdala; Female; Heart; Humans; Interoception; | 2016 |
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma.
Topics: Adrenal Glands; Adult; Baroreflex; Blood Pressure Monitoring, Ambulatory; Epinephrine; Female; Gluca | 2007 |
beta-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder.
Topics: Acute Disease; Adult; Ambulatory Care; Biomarkers; Control Groups; Cyclic AMP; Female; Humans; Isopr | 2008 |
Effects of isoproterenol infusions on heart rate variability in patients with panic disorder.
Topics: Adrenergic beta-Agonists; Adult; Anxiety; Female; Heart Rate; Humans; Infusions, Intravenous; Isopro | 1995 |
Decreased lymphocyte beta-adrenoreceptor function correlates with less agoraphobia and better outcome in panic disorder.
Topics: Adult; Agoraphobia; Behavior Therapy; Combined Modality Therapy; Down-Regulation; Female; Humans; Is | 1993 |
QT interval variability in panic disorder patients after isoproterenol infusions.
Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Electrocardiography; Female; Heart Rate; Huma | 2001 |